️ President Shavkat Mirziyoyev has sharply criticized regional governors and officials for the inefficient use of pharmaceutical zones and inadequate analysis of drug demand. The head of state emphasized that despite established capacities, many allocated lands remain idle, new production facilities are not being launched, and existing enterprises are losing turnover. This approach is hindering the localization of pharmaceutical production and jeopardizing the country's drug security.
️ The president noted that the republic has five specialized pharmaceutical zones totaling 136 hectares with ready infrastructure, but the efforts of regional governors to fill them have been insufficient. In the "Bo‘stonliq" zone, 14 hectares have been vacant since 2017, and in the Jizzakh pharmaceutical zone, not a single package of drugs was produced last year. In Jizzakh and Samarkand regions, no new production was launched during the same period, while in Bukhara and Khorezm regions, results were limited to isolated projects with relatively small sums.
️ Meanwhile, the turnover of 96 operating enterprises in the republic decreased by 312 billion soums, clearly indicating the inability of regional authorities to support existing capacities and create conditions for their development. The head of state also pointed to systemic gaps in planning: governors and their deputies for investments do not study import structures and real population demand, nor do they hold regular meetings with producers to discuss localization issues.
️ Without a clear understanding of which drugs are in demand on the market, it is impossible to ensure drug security and reduce dependence on foreign supplies. At the same time, the president noted that the potential for developing the pharmaceutical sector in the country is significant: Uzbekistan has 58 enterprises producing about 2,500 types of drugs.
️ Many in-demand medications have simple formulas and do not require complex technologies. For example, painkillers such as ibuprofen, paracetamol, and diclofenac are already produced by more than 20 domestic companies. Similar potential exists in the production of B, C, and D group vitamins, as well as iodine, zinc, magnesium, and iron preparations, which can be produced domestically without excessive certification requirements while strictly adhering to quality standards.
️ It was previously reported that by 2030, the share of domestic drugs on Uzbekistan's internal market is planned to reach 70%, and within the next five years, the volume of product exports is expected to be increased to $1 billion.
Source: podrobno.uz